WO2009094427A1 - 4-pyridinone compounds and their use for cancer - Google Patents
4-pyridinone compounds and their use for cancer Download PDFInfo
- Publication number
- WO2009094427A1 WO2009094427A1 PCT/US2009/031665 US2009031665W WO2009094427A1 WO 2009094427 A1 WO2009094427 A1 WO 2009094427A1 US 2009031665 W US2009031665 W US 2009031665W WO 2009094427 A1 WO2009094427 A1 WO 2009094427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- carboxylic acid
- added
- reaction
- Prior art date
Links
- 0 *c(cc1)ccc1OC1=CC=*C2C=C[C@]12 Chemical compound *c(cc1)ccc1OC1=CC=*C2C=C[C@]12 0.000 description 2
- ZAYIEAYTDSSIAG-UHFFFAOYSA-N Clc1c(N=C(c2ccccc2)c2ccccc2)nccc1 Chemical compound Clc1c(N=C(c2ccccc2)c2ccccc2)nccc1 ZAYIEAYTDSSIAG-UHFFFAOYSA-N 0.000 description 1
- SFLFBNIUTUIIHM-UHFFFAOYSA-N NC(c(nccc1Oc(ccc(NC(C(C(N(C=C2)c(cc3)ccc3F)=O)=C2I)=O)c2)c2F)c1Cl)=O Chemical compound NC(c(nccc1Oc(ccc(NC(C(C(N(C=C2)c(cc3)ccc3F)=O)=C2I)=O)c2)c2F)c1Cl)=O SFLFBNIUTUIIHM-UHFFFAOYSA-N 0.000 description 1
- IHAFMSZIVGDZTC-UHFFFAOYSA-N Nc(cc1)ccc1Oc1ccncc1 Chemical compound Nc(cc1)ccc1Oc1ccncc1 IHAFMSZIVGDZTC-UHFFFAOYSA-N 0.000 description 1
- PDYXPCKITKHFOZ-UHFFFAOYSA-N Nc(nccc1Oc(ccc(NC(C2=CNC=C(c(cc3)ccc3F)C2=O)=O)c2)c2F)c1Cl Chemical compound Nc(nccc1Oc(ccc(NC(C2=CNC=C(c(cc3)ccc3F)C2=O)=O)c2)c2F)c1Cl PDYXPCKITKHFOZ-UHFFFAOYSA-N 0.000 description 1
- YAVQQLRMIQRJGV-UHFFFAOYSA-N O=C(C1=CNC=C(c(cc2)ccc2F)C1=O)Nc(cc1)cc(F)c1Oc1ccnc(N=C(c2ccccc2)c2ccccc2)c1Cl Chemical compound O=C(C1=CNC=C(c(cc2)ccc2F)C1=O)Nc(cc1)cc(F)c1Oc1ccnc(N=C(c2ccccc2)c2ccccc2)c1Cl YAVQQLRMIQRJGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention generally relates to processes for preparing pyridinone compounds.
- Met also referred to as hepatocyte growth factor receptor (HGFR)
- HGFR hepatocyte growth factor receptor
- Met is expressed predominantly in epithelial cells but has also been identified in endothelial cells, myoblasts, hematopoietic cells, and motor neurons.
- Overexpression of hepatocyte growth factor and activation of Met has been associated with the onset and progression in a number of different tumor types as well as in the promotion of metastatic disease.
- U.S. Patent Application Publication 2008/0114033 Al discloses a pyridinone compound useful for treating Met-related cancers.
- the disclosed pyridinone compound which comprises an amide linkage and an amine substituted pyridyl group, has the structure of Formula (Ia):
- the reference also discloses a multistep synthesis process for preparing the pyridinone compound.
- This process includes the reaction between an aniline compound and a carboxylic acid compound to form the amide linkage in the compound of Formula (Ia).
- the disclosed process also includes a Hofmann Rearrangement reaction to convert an amide substituent to an amine group, to provide the amine substituted pyridyl group in the structure of Formula (Ia).
- One difficulty is that the Hofmann Rearrangement step was not readily adaptable to commercial scale synthesis.
- a new process will employ less expensive starting materials.
- Desired is a process that is suitable for preparing larger quantities of the pyridinone compound of Formula (I) than is typically prepared by laboratory scale processes. Also desired is a process that provides higher yields of the pyridinone compound of Formula (I) than the previously disclosed processes.
- the present invention is directed to one or both of these, as well as other important aspects.
- G is each R 1 is independently alkyl, haloalkyl, halogen, or CN; each R 2 is independently alkyl, haloalkyl, halogen, or CN;
- R 3 is phenyl substituted with alkyl, haloalkyl, halogen, or CN; each R 4 is independently alkyl, haloalkyl, alkoxy, halogen, or CN; m is zero, 1, 2, 3, or 4; n is zero, 1, 2, or 3; p is zero, 1 or 2; and q is zero, 1, 2, or 3.
- alkyl and “alk” refer to a straight or branched chain alkane
- alkyl and/or “alk” groups include, but are not limited to, for example, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, and dodecyl.
- lower alkyl refers to an “alkyl” and/or “alk” group containing from 1 to 4 carbon atoms and preferably from 1 to 2 carbon atoms.
- the subscript refers to the number of carbon atoms the group may contain.
- the term “Co-C 4 alkyl” includes a bond and an alkyl group containing 1 to 4 carbon atoms
- the term “Ci-C 4 alkyl” refers to alkyl groups containing 1 to 4 carbon atoms.
- Exemplary lower alkyl groups include, but are not limited to, for example, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, and isobutyl.
- halogen and “halo” refer to fluorine, chlorine, bromine, and iodine.
- haloalkyl refers to an alkyl group substituted at one or more positions with halo substituents.
- exemplary haloalkyl groups include, but are not limited to, haloalkyls having a single halo substituent such as -CH 2 F, -CH 2 Cl, and - CH 2 Br, and haloalkyls having multiple halo substituents such as -CHF 2 , -CF 3 , - CHCl 2 , and -CCl 3 .
- cyano refers to -CN.
- amine refers to -NH 2 .
- carboxylic acid refers to -C(O)OH, which may be depicted as:
- alkoxy refers to -O-alkyl. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, n-butoxy, and t-butoxy.
- amide linkage refers to -NHC(O)-, which may be depicted as:
- the pyridinone compound of Formula (V) may exist in the enol form represented by the formula below:
- compound of Formula (V) and “compound of Formula (V-enol)” refer to the compound of Formula (V) in the keto form, the enol form, or any mixture comprising the keto and enol forms.
- One aspect of the present invention relates to a process for preparing the compound of Formula (I) in which the compound of Formula (I) comprises an amide linkage and a pyridyl group substituted with an amine.
- the amide linkage in the compound of Formula (I) can be prepared by reacting the carboxylic acid compound of Formula (III) or an activated carboxylic acid compound thereof, with the aniline compound of Formula (II), wherein the aniline compound of Formula (II) comprises a pyridyl group having a protected amine group (PAm).
- the amide linkage is formed by reaction of the amine group attached to the phenyl ring (the aniline group of the compound of Formula (H)) and the carboxylic acid group of the compound of Formula (III) or an activated carboxylic acid group thereof.
- the protected amine group minimizes and/or eliminates competing side reactions between the amine functionality attached to the pyridyl group of the compound of Formula (II) and the carboxylic acid compound of Formula (III) or an activated carboxylic acid compound thereof.
- the protected amine group (PAm) comprises a nitrogen atom that is bonded directly to the pyridyl ring and further comprises one or two blocking groups attached to the nitrogen atom.
- the blocking groups minimize or eliminate reactions of the nitrogen atom bonded to the pyridyl ring during the formation of the amide linkage between the aniline compound and the carboxylic acid compound.
- the protected amine group is nonreactive or substantially nonreactive during the formation of the amide linkage. After the formation of the amide linkage, the blocking groups are removed to provide the amine substituted pyridyl group of the compound of Formula (I).
- the protected amine group expressly excludes groups in which the nitrogen atom is not directly attached to the pyridal ring, such as -C(O)NH 2 .
- Various protected amine groups may be employed in the process of the present invention. Examples of suitable protected amine groups include, but are not limited to, imines, alkylamines, arylamines, carbamates, amides, imides, benzylamines, allylamines, silylamines, phosphonamides, sulfonamides, and triazinanones.
- Preferred protected amine groups include imines, amides, carbamates, imides, sulfonamides, silylamines, benzylamines, allylamines, phosphonamides, and triazinanones. More preferred protected amine groups include imines, amides, carbamates, imides, and sulfonamides.
- a suitable catalyst such as an acid or a base catalyst.
- Another route is the reaction of an activated carboxylic acid compound of Formula (III) and the aniline compound of Formula (II).
- the activated carboxylic acid compound of Formula (III) can be prepared by contacting the carboxylic acid compound of Formula (III) with an activating agent to provide the activated carboxylic acid compound of Formula (III), prior to reaction with the aniline compound of Formula (II).
- the step of reacting a carboxylic acid compound of Formula (III) and an aniline compound of Formula (II) includes both the reaction between the carboxylic acid compound of Formula (III) and/or the activated carboxylic acid compound thereof, and the aniline compound of Formula (II).
- the process of the present invention comprises preparing the compound of Formula (I) by a) reacting an activated carboxylic acid compound of Formula (III) and an aniline compound of Formula (II) to provide a compound of Formula (IV); and b) converting the protected amine group attached to said compound of Formula (IV) to an amine group to provide said compound of Formula (I).
- an activated carboxylic acid compound of Formula (IIIc) such as an acid halide compound of Formula (IIIc)
- X is an activating group such as, for example, chlorine.
- the activated carboxylic acid compounds of Formula (IIIc) can be prepared by contacting the carboxylic acid compound of Formula (III) with various adjuvants including, but not limited to, acid halides including acid chlorides such as oxalyl chloride (COCl) 2 , sulfonylchloride (SO 2 Cl), Vilsmeier reagent (N- chloromethylene-NN-dimethyl ammonium chloride), phosphorylchloride (POCI3), PO(OEt) 2 Cl, and pivaloylchloride (t-BuCOCl); uronium salts such as O-benzotriazol- l-yl-l,l,3,3-tetramethyluronium tetrafluoroborate (TBTU) and O-(7-azabenzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HATU); dicarbodiimides such as di
- Preferred reagents include dicyclohexylcarbodiimide, N-(3-dimethylaminopropyl)-N'-ethyldicarbodiimide, Vilsmeier reagent, oxalyl chloride, thionyl chloride, propylphosphonic anhydride, diethyl chlorophosphate, pivaloyl chloride, chloroformates including tert-butyl chloroformate, iso-butylchloroformate, isopropylchloroformate, trimethylsilyl- isothiocyanate, and Mitsunobu reagents (diethylazodicarboxylate and triphenylphosphine).
- More preferred reagents include Vilsmeier reagents, oxalyl chloride, and thionyl chloride.
- the reaction of the carboxylic acid compound of Formula (III) or the activated carboxylic acid compound of Formula (IIIc) with the aniline compound of Formula (II) can be conducted in the presence of various synthesis adjuvants, including, for example, organic bases such as triethyl amine, potassium tert-butoxide, sodium 2-ethylhexanoate, and N,N-diisopropylethylamine (DIPEA); and inorganic bases such as sodium carbonate and cesium carbonate.
- organic bases such as triethyl amine, potassium tert-butoxide, sodium 2-ethylhexanoate, and N,N-diisopropylethylamine (DIPEA)
- DIPEA N,N-diisopropylethylamine
- inorganic bases such as sodium carbon
- Suitable adjuvants include acylation catalysts such as 4-dimethylaminopyridine (DMAP), 1- hydroxybenzotriazole, 2-pyridone, l,4-diazabicyclo[2.2.2]octane (DABCO), 1,8- diazabicylco[5.4.0]undec-7-ene (DBU), and 2,6-lutidine.
- DMAP 4-dimethylaminopyridine
- DABCO 1- hydroxybenzotriazole
- DBU 1,8- diazabicylco[5.4.0]undec-7-ene
- 2,6-lutidine 2,6-lutidine.
- Preferred synthesis adjuvants include organic bases such as triethyl amine, potassium tert-butoxide, and sodium 2-ethylhexanoate; and acylation catalysts such as 2-pyridone, A- dimethylaminopyridine, 1-hydroxybenzotriazole, l,4-diazabicyclo[2.2.2]octane, 1,8- diazabicylco[5.4.0]undec-7-ene, and 2,6-lutidine. Most preferred synthesis adjuvants include sodium 2-ethylhexanoate.
- the reaction between a carboxylic acid compound of Formula (III) or an activated carboxylic acid compound Formula (IIIc), and the aniline compound of Formula (II) can be conducted in various solvents or mixtures thereof.
- suitable solvents include, but are not limited to, polar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such tetrahydrofuran, 2-methyl tetrahydrofuran, methyl t-butyl ether, and diethoxymethane; hydrocarbons such as benzene, toluene, hexanes, and heptane; halogenated solvents such as dichloromethane and 1,2-dichloroethane; acetates such as ethyl acetate, isopropyl acetate, and butyl acetate, and other solvents such as acetonitrile, methyl vinyl ketone, N,N
- Preferred solvents include etheral solvents such tetrahydrofuran, 2-methyl tetrahydrofuran, and diethoxymethane; hydrocarbons such as toluene and heptane; and halogenated solvents such as dichloromethane and 1,2-dichloroethane. More preferred solvents include halogenated solvents such as dichloromethane and 1,2- dichloroethane.
- Suitable reaction temperatures for the reaction between the carboxylic acid compound of Formula (III) or the activated carboxylic acid compound thereof, and the aniline compound of Formula (II) include temperatures in the range of from about -50 0 C to about 150 0 C, preferably in the range of from -25°C to about 100 0 C, and more preferably in the range of from 0 0 C to 50 0 C.
- the activated carboxylic acid compound of Formula (Ilia) is prepared by reacting the carboxylic acid compound of Formula (III) and oxalyl chloride in a halogenated solvent, such as dichloromethane, and/or dimethyl formamide at a temperature in the range of from -20 0 C to -40 0 C.
- a halogenated solvent such as dichloromethane, and/or dimethyl formamide
- STEP II REMOVAL OF PROTECTING GROUP TO GENERATE AMINE
- the protected amine group attached to the pyridyl group of said compound is converted to an amine group to provide the compound of Formula (I).
- Various methods may be employed to convert the protected amine group to the amine group without affecting the amide linkage. Examples of suitable methods include: a) Treatment with organic, inorganic, or Lewis acids in the presence of water. Suitable acids include, for example, formic acid, acetic acid, methanesulfonic acid, trifluoroacetic acid, citric acid, hydrochloric acid, sulfuric acid phosphoric acid, magnesium triflate, and lithium bromide.
- Suitable acids include, for example, formic acid, acetic acid, magnesium triflate, and lithium bromide.
- oxidants such as eerie ammonium nitrate (CAN) and 2,3-dichloro- 5,6-dicyano-p-benzoquinone (DDQ).
- Suitable solvents for conversion of the protected amine group include, for example, polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such as tetrahydrofuran, 2-methyl tetrahydrofuran, methyl t-butyl ether, and diethoxymethane; hydrocarbons such as toluene, heptane, benzene, and hexanes; halogenated solvents such as dichloromethane and 1,2-dichloroethane; acetates such as ethyl acetate, isopropyl acetate, and butyl acetate; alcohols such as methanol, ethanol, and isopropanol; and other solvents such as acetonitrile, methyl vinyl ketone, and N,N-dimethylacetamide; and mixtures thereof.
- polar aprotic solvents such as dimethylformamide,
- Preferred solvents include tetrahydrofuran, 2-methyl tetrahydrofuran, methyl t-butyl ether, toluene, N-methylpyrrolidinone, dimethylformamide, NN-dimethylacetamide, and ethanol.
- Suitable reaction temperatures for converting a protected amine group to an amine group include temperatures in the range of from about -78°C to about
- 200 0 C preferably in the range of from -25°C to about 150 0 C, and more preferably in the range of from 0 0 C to 100 0 C.
- the compound of Formula (I) and the compound of Formula (IV) can be isolated and/or purified by various methods known in the art. Suitable methods include chromatography, crystallization, filtration, and distillation.
- PAm is an imine, imide, carbamate, amide, or sulfonamide. More preferably, PAm is an imine or imide.
- the process for preparing a compound of Formula (I) is employed to prepare compounds of Formula (I) in which R 1 is halogen and m is zero, 1, or 2.
- m is 1.
- R 1 is F or Cl, and more preferably F. More preferably, R 1 is F and m is 1.
- the process for preparing a compound of Formula (I) is employed to prepare compounds of Formula (I) in which R is halogen and n is zero, 1, or 2.
- n is 1.
- R 2 is F or Cl, and more preferably F. More preferably, R 2 is F and n is 1.
- the process for preparing a compound of Formula (I) is employed to prepare compounds of Formula (I) in which R is phenyl substituted with Ci -C 4 alkyl, C 1 -C 3 halo alkyl, halogen, or CN; preferably, R is methyl, ethyl, trifluoromethyl, pentafluoroethyl, halogen, or CN; and more preferably, R 3 is methyl, trifluoromethyl, F, Cl, or CN.
- the process for preparing a compound of Formula (I) is employed to prepare compounds of Formula (I) in which R is phenyl substituted with halogen; more preferably, R 3 is phenyl substituted with F or Cl; and still more preferably, R is a fluorophenyl, including, for example, 4-fluorophenyl.
- the process for preparing a compound of Formula (I) is employed to prepare the pyridinone compound N-(4-(2-amino-3-chloropyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo-l,2-dihydropyridine-3- carboxamide, which has the structure represented by Formula (Ia)
- U.S. Patent Application Publication 2008/0114033 Al discloses the Compound of Formula (Ia) and is incorporated herein in its entirety.
- U. S Provisional Patent Application 61/022848 discloses the Compound of Formula (Ib) and prodrugs thereof, and is incorporated herein in its entirety. The present application claims priority to U.S. Provisional Patent application 61/022848.
- Met kinases inhibitors are useful in the treatment of cancers, such as, for example, bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma (MFH), fibrosarcoma, glioblastomas/astrocytomas, melanoma, and mesothelioma.
- cancers such as, for example, bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma (MFH), fibrosarcoma, glioblastomas/astrocytomas, mel
- a process is provided for preparing N-(4-(2-amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo-l,2- dihydropyridine-3-carboxamide, the compound of Formula (Ia)
- the process comprises the steps of: (a) reacting an aniline compound of Formula (lib):
- PAm is a protected amine group
- PAm is a protected amine group; and b) converting said protected amine group attached to said compound of Formula (IVb) to an amine group to provide said compound of Formula (Ib).
- the compound of Formula (Ib) may be provided as a prodrug, as disclosed in U.S. Provisional Application 61/022848.
- One embodiment provides a compound of Formula (Villa) having the structure: (Villa) wherein PAm is defined hereinabove.
- One example of a compound of this embodiment is 3-chloro-2-(diphenylmethyleneamino) pyridin-4(lH)-one, which has the structure of Formula (3A):
- a process comprising the step of reacting 2,3-dichloropyridine and benzophenone imine to provide 3-chloro-2- (diphenylmethyleneamino) pyridin-4(lH)-one.
- solvents include, but are not limited to, polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxymethane; hydrocarbons such as toluene, heptane, benzene, and hexanes; halogenated solvents such dichloromethane and 1,2- dichloroethane; acetates such as ethyl acetate, isopropyl acetate, and butyl acetate; other solvents such as acetonitrile and methyl vinyl ketone; or mixtures thereof.
- polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone
- etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxy
- the reaction can be conducted in the presence of various synthesis adjuvants such as catalysts, bases, and/or ligands.
- suitable catalysts include, but are not limited to, palladium catalysts such as palladium acetate and tetrakis(triphenylphosphine)palladium; copper catalysts such as copper (I) halides and copper (II) trifluoromethanesulfonate; and nickel catalysts such as Bis(l,5- cyclooctadiene)nickel (0); which can be present in range of from 0.0001 to 1.5 equivalents.
- Suitable ligands include, but are not limited to, phosphine ligands such as 2,2'-bis(diphenylphosphino)-l,l'-binaphthylene, P(alkyl) 2 (phenyl), P(alkyl)(phenyl) 2 , and P(phenyl) 3 ; and nitrogen heterocycles such as imidazole and hydroxy pyridine, which can be present in the range of from 0.0001 to 1.5 equivalents.
- suitable bases include, but are not limited, inorganic bases such as sodium carbonate, and cesium carbonate; and organic bases such as triethylamine and potassium butoxide; which can be present in the range of from 1 to 10 equivalents.
- the reaction of this embodiment is conducted in at least one solvent selected from tetrahydrofuran, 2-methyl tetrahydrofuran, diethoxymethane, toluene, and/or heptane; and more preferably, tetrahydrofuran, 2- methyl tetrahydrofuran, and/or diethoxymethane.
- the reaction of this embodiment is conducted in the presence of at least base selected from sodium carbonate and/or cesium carbonate.
- the reaction of this embodiment is conducted in the presence of at least one palladium catalyst, for example, palladium acetate and/or tetrakis(triphenylphosphine)palladium.
- the reaction of this embodiment is conducted in the presence of at least one phosphine ligand selected from 2,2'-bis(diphenylphosphino)- 1 , 1 '-binaphthylene, P(alkyl) 2 (phenyl), P(alkyl)(phenyl) 2 , and P(phenyl)3.
- the reaction of this embodiment can be conducted in the presence of cesium carbonate, palladium acetate, and 2,2'- bis(diphenylphosphino)- 1,1 '-binaphthylene in at least one solvent selected from tetrahydrofuran, 2-methyl tetrahydrofuran, and/or diethoxymethane.
- the reaction to prepare 3-chloro-2-(diphenylmethyleneamino) pyridin- 4(lH)-one can be conducted at temperatures in the range of from about -78°C to about 200 0 C, preferably in the range of from -25°C to about 150 0 C, and more preferably in the range of from 0 0 C to 100 0 C.
- the reaction product can be separated and purified by methods known in the art.
- One embodiment provides a compound of Formula (Vb) having the structure:
- PAm is defined hereinabove.
- One example of a compound of this embodiment is 3-chloro-2-(diphenylmethyleneamino) pyridin-4(lH)-one, which has the structure of Formula (3B):
- One embodiment provides a compound of Formula (Vila)
- each R 1 is independently alkyl, haloalkyl, halogen, or CN; each R 2 is independently alkyl, haloalkyl, halogen, or CN; m is zero, 1, 2, 3, or 4; n is zero, 1, 2, or 3; and PAm is a protected amine group.
- R 1 is halogen, m is 1, R 2 is halogen, and n is 1.
- PAm is an imine, imide, carbamate, amide, or sulfonamide. More preferably, PAm is an imine or imide.
- PAm is defined hereinabove.
- PAm is an imine, imide, carbamate, amide, or sulfonamide. More preferably, PAm is an imine or imide.
- One embodiment provides an aniline compound of Formula (II)
- each R 1 is independently alkyl, haloalkyl, halogen, or CN; each R 2 is independently alkyl, haloalkyl, halogen, or CN; m is zero, 1, 2, 3, or 4; n is zero, 1, 2, or 3; and PAm is a protected amine group.
- R 1 is halogen, m is 1, R 2 is halogen, and n is 1.
- PAm is an imine, imide, carbamate, amide, or sulfonamide. More preferably, PAm is an imine or imide.
- PAm is defined hereinabove.
- PAm is an imine, imide, carbamate, amide, or sulfonamide. More preferably, PAm is an imine or imide.
- a process for preparing a compound of Formula (V), comprising the step of oxidizing a compound of Formula (VIII).
- the compound of Formula (VII) converted to the compound of Formula (V) by deprotonation, followed by direct oxidation; or alternatively, by deprotonation, followed by boralation, and then oxidation.
- the process of this embodiment can be employed to prepared 3-chloro-2-(diphenylmethyleneamino) pyridin-4(lH)-one by oxidizing 3-chloro-2-(diphenylmethyleneamino) pyridin-4(lH)- one.
- solvents include, but are not limited to, polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxymethane; hydrocarbons such as toluene, heptane, benzene, and hexanes; and halogenated solvents such dichloromethane and 1,2- dichloroethane, or mixtures thereof.
- polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone
- etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxymethane
- hydrocarbons such as toluene, heptane, benzene, and hexanes
- halogenated solvents such dichloromethane and 1,2-
- the reaction can be conducted in the presence of various synthesis adjuvants including oxidants such as hydrogen peroxide, sodium percarbonate, potassium peroxymonosulfate (OxoneTM compound), and sodium tetrafluoroborate; peroxides such as t-butyl hydrogen peroxide and m- chloroperoxybenzoic acid; trialkoxyborates; and/or lithium amides such as lithium diisopropylamide. Suitable amounts of peroxide, trialkoxyborates, and lithium amide include 1 to 4 equivalents each.
- Preferred solvents include tetrahydrofuran, 2-methyl tetrahydrofuran, diethoxymethane, toluene, and heptane, or a mixture thereof.
- Preferred oxidants include hydrogen peroxide, sodium percarbonate, and potassium peroxymonosulfate.
- the process of this embodiment can be employed to prepare 3-chloro-2-(diphenylmethyleneamino) pyridin-4(lH)-one by reacting 3- chloro-2-(diphenylmethyleneamino) pyridin-4(lH)-one in the presence of 1-3 equivalents of lithium diisopropylamide, 1-4 equivalents of triisopropoxyborate, and an oxidizing agent selected from sodium percarbonate and/or potassium peroxymonosulfate in a solvent selected from tetrahydrofuran, 2-methyl tetrahydrofuran, diethoxymethane, toluene, and heptane, or a mixture thereof.
- a process is provided for preparing the compound of Formula (VIIb), comprising the step of reacting a compound of Formula (Vb) with 1 ,2-difluor
- solvents include, but are not limited to, polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxymethane; hydrocarbons such as toluene, heptane, benzene, and hexanes; halogenated solvents such dichloromethane and 1,2- dichloroethane; acetates such as ethyl acetate, isopropyl acetate, and butyl acetate; other solvents such as acetonitrile and methyl vinyl ketone; or mixtures thereof.
- polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone
- etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxy
- the reaction can be conducted in the presence of various synthesis adjuvants including bases.
- suitable bases include, but are not limited, inorganic bases such as sodium carbonate, lithium carbonate, and cesium carbonate; and organic bases such as triethylamine and potassium butoxide.
- the process of the present embodiment can be conducted at temperatures in the range of from about -78°C to about 200 0 C, preferably in the range of from -25°C to about 150 0 C, and more preferably in the range of from 0 0 C to 100 0 C.
- the reaction product can be separated and purified by methods known in the art.
- the reaction of this embodiment is conducted in a solvent selected from dimethylformamide, dimethyl sulfoxide, and N- methylpyrrolidinone, or mixtures thereof.
- the reaction of this embodiment is conducted in the presence of at least inorganic base, such as sodium carbonate, lithium carbonate, and/or cesium carbonate.
- the process of the present embodiment can be conducted in the presence of lithium carbonate and/or cesium carbonate in a solvent selected from dimethyl formamide, N-methylpyrrolidinone, and mixtures thereof.
- a process for preparing an aniline compound of Formula (II) comprising the step of converting a compound of Formula (VII) to a compound of Formula (II)
- the process of this embodiment can be used to prepare the aniline compound of Formula (lib) from the compound of Formula (VIIb).
- solvents include, but are not limited to, polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone; etheral solvents such as tetrahydrofuran, 2- methyl tetrahydrofuran, and diethoxymethane; alcohols such as ethanol and isopropanol; hydrocarbons such as toluene, heptane, benzene, and hexanes; halogenated solvents such dichloromethane and 1,2-dichloroethane; acetates such as ethyl acetate, isopropyl acetate, and butyl acetate; other solvents such as acetonitrile and methyl vinyl ketone; or mixtures thereof.
- polar aprotic solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidinone
- etheral solvents such as tetrahydrofuran, 2-
- the reaction can be conducted in the presence of various synthesis adjuvants including, but not limited to, bases, reductants, transition metals, catalysts, and a hydrogen source.
- suitable reductants include, but are not limited to, sodium dithionite sodium sulfide, ammonium sulfide, FeSO 4 , and sodium borohydride.
- suitable transition metals include, but are not limited to, Fe, Pd, Rh, and Ir.
- Suitable hydrogen sources include hydrogen gas and formic acid.
- suitable bases include, but are not limited, inorganic bases such as sodium carbonate, lithium carbonate, and cesium carbonate; and organic bases such as triethylamine and potassium butoxide.
- the process of the present embodiment can be conducted at temperatures in the range of from about -78°C to about 200 0 C, preferably in the range of from -25°C to about 150 0 C, and more preferably in the range of from 0 0 C to 100 0 C.
- the reaction product, the compound of Formula (II) can be separated and purified by methods known in the art.
- the reaction of this embodiment is conducted in a solvent selected from dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidinone, tetrahydrofuran, 2-methyl tetrahydrofuran, diethoxymethane, ethanol, isopropanol, or mixtures thereof.
- the reaction of this embodiment is conducted in the presence of a reductant selected from sodium sulfide, ammonium sulfide, and FeSO 4 .
- the reaction of this embodiment is conducted in the present of a transition metal selected from Pd or Ni.
- the process of the present embodiment can be conducted in the presence of ammonium sulfide, nickel such as Raney-Ni, a hydrogen source, and base in a solvent selected from isopropanol, ethanol, tetrahydrofuran, 2-methyl tetrahydrofuran, and mixtures thereof.
- a process for preparing the aniline compound of Formula (II) comprising the steps of: a) reacting a pyridinone compound of Formula (V):
- X is F or Cl.
- Solvents, synthesis adjuvants, and reaction conditions are disclosed hereinabove.
- a process for preparing the aniline compound of Formula (Ha) comprising the steps of: a) reacting a pyridinone compound of Formula (Va):
- X is F or Cl.
- a process for preparing the aniline compound of Formula (lib) comprising the steps of: a) reacting a pyridinone compound of Formula (Vb):
- step (a) and step (b) Suitable solvents, synthesis adjuvants, and reaction conditions for step (a) and step (b) are disclosed hereinabove and in the Examples.
- reaction mixture was stirred for 2 hours at 20 0 C.
- the reaction mixture was cooled to 0 0 C and 50 L of water were added to the reaction mixture, followed by 30 kg of OXONETM compound (potassium peroxymonosulfate) while maintaining the temperature between 20-25 0 C.
- OXONETM compound potassium peroxymonosulfate
- the reaction mixture was stirred for one hour until the reaction was complete.
- 270 L of water were added and the reaction mixture was stirred for 12 hours.
- the slurry was filtered and the solids washed with 4OL of water.
- the solids were charged back to the reactor and re-slurried in 25L of ethyl acetate for 30 minutes. After filtration, the solids were washed with 10 L of petroleum ether.
- charcoal 0.7 kg was charged to the aqueous layer and the layer was filtered through a celite bed. To the filtrate was added 1.5 N HCl until the pH had reached 2.0. The resulted slurry was stirred for 20 min at room temperature. The solids were filtered off, washed with water (15 L) and dried under vacuum at 50-55 0 C until the loss on drying was less than 5 wt%. The crude product was suspended in ethyl acetate (5 L) and slurried for 15 min at 40 0 C.
- Step 8 Preparation of 7V-(4-(3-chloro-2-(diphenylmethyleneamino)pyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo-l,2-dihydropyridine-3- carboxamide
- the reaction mixture was held at 10 0 C for approximately 2.5h, until HPLC indicated ⁇ 0.5 relative area percent of starting material.
- Water (500 mL) and MTBE (500 mL) were added and the reaction mixture was warmed to 20 0 C.
- IN NaOH (184.08 g, 177.0 mL, 177 mmoles, 1.20 eq)
- the resulting slurry was cooled to 10 0 C and aged for at least 10 minutes.
- the precipitate was filtered off, and the cake washed with water (2 x 350 mL), followed by a mixture of methanol: MTBE (10:90) (1 x 300 mL).
- reaction mixture was allowed to warm to room temperature, while continuing to bubble CO 2 through the solution.
- the reaction was quenched with saturated aqueous ammonium chloride solution (-50 mL) and stirred at rt under an atmosphere of air for 5 min.
- the reaction mixture was diluted with water (-150 mL) and extracted with ethyl acetate (2 x 75 mL) to remove any remaining starting material.
- the aqueous layer was acidified to pH 1-2 with IN aqueous HCl solution and extracted with ethyl acetate (2 x 100 mL).
- the aqueous layer was back- extracted with 300 mL ethyl acetate.
- the combined organic phases were washed with 10% aqueous lithium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo.
- the resulting brown solid was suspended in ethyl acetate, filtered and washed with ether to give the product as a tan solid (7.4 g).
- the filtrate was concentrated in vacuo and then purified by flash chromatography on silica gel (2% methanol / ethyl acetate).
- Step 7 Preparation of l-(4-Fluorophenyl)-4-iodo-2-oxo-l,2-dihydropyridine-3- carboxylic acid
- Example 3 To a solution of N-(4-(3 -chloro-2-(diphenylmethyleneamino)pyridin-4- yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-l,4-dihydropyridine-3-carboxamide (410 mg, 0.65 mmol) in THF (10 mL) at room temperature was added aqueous HCl (2 M, 0.81 mL, 1.62 mmol). The reaction mixture was stirred at room temperature for 1 h and then concentrated in vacuo. Cold 5% aq. ⁇ aHC ⁇ 3 (5 mL) was then added to the residue.
- a first solution was prepared by dissolving 2.3-Dichloropyridine (100 g, 0.68 mol) and triisopropyl borate (315 mL, 1.37 mol) in THF (150 mL). The resulting solution was cooled to - 10 0 C.
- a second solution was prepared by dissolving diisopropylamine (150 mL, 1.07 mol) in THF (500 mL). The second solution was cooled to -10 0 C and under nitrogen, w-butyl lithium (420 mL, 1.05 mol) was added over 20 min. After stirring for 10 min, the second solution was added slowly to the first solution via vacuum transfer.
- reaction mixture was stirred for 3 hrs at 22°C until HPLC analysis indicated reaction completion.
- Water (1.00 L) was added to the mixture, followed by addition of sodium percarbonate (238 g) in two portions.
- the resulting mixture was allowed to stir at 20 0 C for 1 h.
- the pH of the mixture was adjusted to pH 2-3 by addition of cone. HCl (300 mL).
- solid NaHSO 3 85 g was added.
- the aqueous layer was separated and extracted with toluene (150 mL).
- the combined organic layers were washed with water (two times 100 mL) and concentrated by atmospheric distillation (distillation temperature up to 90 0 C) to about 500 mL.
- the mixture was cooled to 50 0 C and silicagel (20 g) and xylene (300 mL) were added. The suspension was stirred for 30 min at 50-55 0 C and filtered on a Buechner funnel. The filter cake was washed with xylene (two times 100 mL). The filtrates were combined, washed with water (two times 150 mL) and concentrated to about 150 mL by distillation on a rotary evaporator. After cooling to 25°C, heptane (300 mL) was added to the mixture. The resulting slurry was stirred at 25°C for 16 hrs.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/863,713 US8558000B2 (en) | 2008-01-23 | 2009-01-22 | 4-pyridinone compounds and their use for cancer |
CN200980110025.4A CN101977905B (en) | 2008-01-23 | 2009-01-22 | 4-pyridinone compounds and their use for cancer |
EP09703743.6A EP2235001B1 (en) | 2008-01-23 | 2009-01-22 | Process for preparing pyridinone compounds |
ES09703743T ES2531396T3 (en) | 2008-01-23 | 2009-01-22 | Process to prepare pyridinone compounds |
JP2010544406A JP5693239B2 (en) | 2008-01-23 | 2009-01-22 | 4-pyridinone compounds and their use for cancer |
US14/026,628 US8754230B2 (en) | 2008-01-23 | 2013-09-13 | 4-pyridinone compounds and their use for cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2284808P | 2008-01-23 | 2008-01-23 | |
US61/022,848 | 2008-01-23 | ||
US12193108P | 2008-12-12 | 2008-12-12 | |
US61/121,931 | 2008-12-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/863,713 A-371-Of-International US8558000B2 (en) | 2008-01-23 | 2009-01-22 | 4-pyridinone compounds and their use for cancer |
US14/026,628 Division US8754230B2 (en) | 2008-01-23 | 2013-09-13 | 4-pyridinone compounds and their use for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009094427A1 true WO2009094427A1 (en) | 2009-07-30 |
Family
ID=40668147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/031665 WO2009094427A1 (en) | 2008-01-23 | 2009-01-22 | 4-pyridinone compounds and their use for cancer |
Country Status (7)
Country | Link |
---|---|
US (2) | US8558000B2 (en) |
EP (1) | EP2235001B1 (en) |
JP (1) | JP5693239B2 (en) |
KR (1) | KR101608096B1 (en) |
CN (1) | CN101977905B (en) |
ES (1) | ES2531396T3 (en) |
WO (1) | WO2009094427A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011137274A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
US8124768B2 (en) | 2008-01-23 | 2012-02-28 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US8933103B2 (en) | 2012-01-31 | 2015-01-13 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9090562B2 (en) | 2011-04-13 | 2015-07-28 | Epizyme, Inc. | Aryl- or heteroaryl-substituted benzene compounds |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9376422B2 (en) | 2011-04-13 | 2016-06-28 | Epizyme, Inc. | Dihidropyridin-2-one benzamine compounds |
US9387202B2 (en) | 2011-11-22 | 2016-07-12 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10442797B2 (en) | 2014-07-07 | 2019-10-15 | Daiichi Sankyo Company, Limited | Pyridone derivatives having tetrahydropyranylmethyl groups |
US11642348B2 (en) | 2012-10-15 | 2023-05-09 | Epizyme, Inc. | Substituted benzene compounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
US8969388B1 (en) | 2012-07-28 | 2015-03-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
CN105153026B (en) * | 2015-08-21 | 2018-02-02 | 江西科技师范大学 | Sorafenib derivative of the amide structure containing biaryl and its preparation method and application |
CN105924389A (en) * | 2015-12-18 | 2016-09-07 | 重庆两江药物研发中心有限公司 | Preparation method of regorafenib intermediate |
WO2019186429A1 (en) * | 2018-03-30 | 2019-10-03 | Sun Pharmaceutical Industries Limited | A process for the preparation of bosutinib |
CN110330479A (en) * | 2019-07-19 | 2019-10-15 | 南京华威医药科技集团有限公司 | A kind of antitumoral compounds and application thereof as AXL inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117867A2 (en) * | 2004-04-23 | 2005-12-15 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3646202A (en) | 1967-11-22 | 1972-02-29 | Merck & Co Inc | Liver fluke compositions containing salicylic acid derivatives |
US4547218A (en) | 1982-10-18 | 1985-10-15 | The Dow Chemical Company | Certain 3-nitro-6-phenoxy-2-pyridyl-oxy-propionates having herbicidal activity |
GB8925368D0 (en) * | 1989-11-09 | 1989-12-28 | Oppolzer Wolfgang | Process for preparing enatiomerically pure alpha-amino acids |
ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
JP2002511386A (en) | 1997-12-22 | 2002-04-16 | イーライ・リリー・アンド・カンパニー | Catalyst for amide forming reaction and method thereof |
CA2333554A1 (en) | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
DE60134679D1 (en) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Nitrogen-containing aromatic heterocycles |
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
KR20030064852A (en) | 2000-12-22 | 2003-08-02 | 이시하라 산교 가부시끼가이샤 | Aniline Derivatives or Salts Thereof and Cytokine Production Inhibitors Containing the Same |
WO2003045921A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
FR2836915B1 (en) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
US6806221B2 (en) | 2002-07-15 | 2004-10-19 | Dow Global Technologies Inc. | Method for preparing a spray-dried composition for use as a polymerization catalyst |
ES2465624T3 (en) | 2003-07-11 | 2014-06-06 | Merck Patent Gmbh | Benzimidazole carboxamides as inhibitors of RAF kinase |
SI2213661T1 (en) | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met Modulators and Methods of Use |
DE10357510A1 (en) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroaryl-substituted benzenes |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
MXPA06012613A (en) | 2004-05-07 | 2007-01-31 | Amgen Inc | Protein kinase modulators and method of use. |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
BRPI0519424B8 (en) | 2004-12-28 | 2021-05-25 | Athenex Inc | compounds, composition and use of said compounds for the preparation of a medicament for preventing or treating a cell proliferation disorder or microbial infection |
US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
CN101198590B (en) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | Novel pyridine derivative and pyrimidine derivative (3) |
CA2619061A1 (en) | 2005-09-13 | 2007-03-22 | Bayer Cropscience Ag | Fungicide pyridinyloxy substituted phenylamidine derivatives |
US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8022222B2 (en) | 2006-01-27 | 2011-09-20 | Array Biopharma, Inc. | Glucokinase activators |
CA2636242A1 (en) | 2006-01-30 | 2008-05-29 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
JP2009529047A (en) * | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | Heterobicyclic pyrazole compounds and uses thereof |
WO2007107005A1 (en) | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
US20080004273A1 (en) | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
WO2008030448A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
SI2089364T1 (en) * | 2006-11-08 | 2013-10-30 | Bristol-Myers Squibb Company | Pyridinone compounds |
-
2009
- 2009-01-22 CN CN200980110025.4A patent/CN101977905B/en active Active
- 2009-01-22 WO PCT/US2009/031665 patent/WO2009094427A1/en active Application Filing
- 2009-01-22 JP JP2010544406A patent/JP5693239B2/en active Active
- 2009-01-22 ES ES09703743T patent/ES2531396T3/en active Active
- 2009-01-22 KR KR1020107018581A patent/KR101608096B1/en active IP Right Grant
- 2009-01-22 US US12/863,713 patent/US8558000B2/en active Active
- 2009-01-22 EP EP09703743.6A patent/EP2235001B1/en active Active
-
2013
- 2013-09-13 US US14/026,628 patent/US8754230B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117867A2 (en) * | 2004-04-23 | 2005-12-15 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124768B2 (en) | 2008-01-23 | 2012-02-28 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US8258118B2 (en) | 2008-01-23 | 2012-09-04 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US8911785B2 (en) | 2010-04-30 | 2014-12-16 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-OXO-1,2-dihydropyridine-3-carboxamide |
WO2011137274A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
US9233948B2 (en) | 2010-04-30 | 2016-01-12 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide |
US9549931B2 (en) | 2011-04-13 | 2017-01-24 | Epizyme, Inc. | Aryl- or heteroaryl-substituted benzene compounds |
US10155002B2 (en) | 2011-04-13 | 2018-12-18 | Epizyme, Inc. | Aryl- or heteroaryl-substituted benzene compounds |
US9376422B2 (en) | 2011-04-13 | 2016-06-28 | Epizyme, Inc. | Dihidropyridin-2-one benzamine compounds |
US11052093B2 (en) | 2011-04-13 | 2021-07-06 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
US9522152B2 (en) | 2011-04-13 | 2016-12-20 | Epizyme, Inc. | Aryl- or heteroaryl-substituted benzene compounds |
US9090562B2 (en) | 2011-04-13 | 2015-07-28 | Epizyme, Inc. | Aryl- or heteroaryl-substituted benzene compounds |
US10420775B2 (en) | 2011-04-13 | 2019-09-24 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
US9855275B2 (en) | 2011-04-13 | 2018-01-02 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
US9387202B2 (en) | 2011-11-22 | 2016-07-12 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US8933103B2 (en) | 2012-01-31 | 2015-01-13 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US11642348B2 (en) | 2012-10-15 | 2023-05-09 | Epizyme, Inc. | Substituted benzene compounds |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10442797B2 (en) | 2014-07-07 | 2019-10-15 | Daiichi Sankyo Company, Limited | Pyridone derivatives having tetrahydropyranylmethyl groups |
US11208403B2 (en) | 2014-07-07 | 2021-12-28 | Daiichi Sankyo Company, Limited | Pyridone derivatives having tetrahydropyranylmethyl groups |
Also Published As
Publication number | Publication date |
---|---|
ES2531396T3 (en) | 2015-03-13 |
JP2011510089A (en) | 2011-03-31 |
EP2235001B1 (en) | 2014-12-24 |
CN101977905A (en) | 2011-02-16 |
US20140012007A1 (en) | 2014-01-09 |
US8754230B2 (en) | 2014-06-17 |
KR20100118581A (en) | 2010-11-05 |
US8558000B2 (en) | 2013-10-15 |
JP5693239B2 (en) | 2015-04-01 |
KR101608096B1 (en) | 2016-03-31 |
EP2235001A1 (en) | 2010-10-06 |
CN101977905B (en) | 2014-07-02 |
US20110295015A1 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2235001B1 (en) | Process for preparing pyridinone compounds | |
JP4675318B2 (en) | Process for the preparation of N-heteroaryl-N-aryl-amines by reacting N-arylcarbamates with halo-heteroaryls and similar processes | |
JP2006517235A5 (en) | ||
KR102128127B1 (en) | Improved process for manufacturing 5-(2,6-di-4-morp holinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | |
JP2019520305A (en) | Method for producing tyrosine kinase inhibitor and derivative thereof | |
EP3265455B1 (en) | Process for preparing ceritinib and intermediates thereof | |
CN116987112A (en) | Improved process for preparing aminopyrimidine derivatives | |
CN110606842B (en) | Process for producing pyridylamino pyrimidine derivative and intermediate thereof | |
KR20040019097A (en) | Process for the Production of Quinazolines | |
US7714127B2 (en) | Process for making heteroaryl amine intermediate compounds | |
KR100510389B1 (en) | Preparation of [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chloro-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide | |
JP2021075535A (en) | Chemical process for preparing pyrimidine derivatives and intermediates thereof | |
JP2019196359A (en) | Chemical process for preparing pyrimidine derivatives and intermediates thereof | |
JPH1059964A (en) | Production of arylamide of heterocyclic aromatic carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980110025.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09703743 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009703743 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5296/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010544406 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107018581 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12863713 Country of ref document: US |